# Type 2 Diabetes Mellitus FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/type-2-diabetes-mellitus

> 10 upcoming FDA catalysts in type 2 Diabetes Mellitus: ormd-0801 8 mg (ORMP) on Apr to Jul 2027 (topline data readout); ormd-0801 8 mg (ORMP) on April 2027 (primary completion); elecoglipron (AZN) on May to Aug 2028 (topline data readout); elecoglipron (AZN) on May to Aug 2028 (topline data readout); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 12, 2025 | [Zepbound (tirzepatide) primary completion](https://sec-api.dev/pdufa/tirzepatide) | LLY | Type 2 Diabetes Mellitus | completed | "NCT04255433 (A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-12 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04255433)) |
| November 19, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes Mellitus | completed | "NCT06065540 (A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-19 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06065540)) |
| July 8, 2026 | [Zepbound (tirzepatide) topline data readout](https://sec-api.dev/pdufa/tirzepatide) | LLY | Type 2 Diabetes Mellitus | completed | "NCT04255433 (A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-12 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-07-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04255433?tab=results)) |
| Apr to Jul 2027 | [Ormd-0801 8 mg topline data readout](https://sec-api.dev/pdufa/ormd-0801) | ORMP | Type 2 Diabetes Mellitus | scheduled | "NCT06731075 (A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-04-25 (ESTIMATED); Lead Sponsor Oramed, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06731075)) |
| April 2027 | [Ormd-0801 8 mg primary completion](https://sec-api.dev/pdufa/ormd-0801) | ORMP | Type 2 Diabetes Mellitus | scheduled | "NCT06731075 (A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2027-04-25 (ESTIMATED); Lead Sponsor Oramed, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06731075)) |
| May to Aug 2028 | [Elecoglipron topline data readout](https://sec-api.dev/pdufa/elecoglipron) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07662213 (A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662213)) |
| May to Aug 2028 | [Elecoglipron topline data readout](https://sec-api.dev/pdufa/elecoglipron) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07664553 (A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07664553)) |
| May 2028 | [Elecoglipron primary completion](https://sec-api.dev/pdufa/elecoglipron) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07662213 (A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662213)) |
| May 2028 | [Elecoglipron primary completion](https://sec-api.dev/pdufa/elecoglipron) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07664553 (A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07664553)) |
| Jul to Oct 2028 | [Farxiga (dapagliflozin) topline data readout](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07662044 (A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-14 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662044)) |
| Jul to Oct 2028 | [Farxiga (dapagliflozin) topline data readout](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07662109 (A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-05 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662109)) |
| July 2028 | [Farxiga (dapagliflozin) primary completion](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07662109 (A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-05 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662109)) |
| July 2028 | [Farxiga (dapagliflozin) primary completion](https://sec-api.dev/pdufa/dapagliflozin) | AZN | Type 2 Diabetes Mellitus | scheduled | "NCT07662044 (A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-14 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07662044)) |

## Drugs

- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Wegovy (semaglutide)](https://sec-api.dev/pdufa/semaglutide) (NVO)
- [Ormd-0801 8 mg](https://sec-api.dev/pdufa/ormd-0801) (ORMP)
- [Elecoglipron](https://sec-api.dev/pdufa/elecoglipron) (AZN)
- [Farxiga (dapagliflozin)](https://sec-api.dev/pdufa/dapagliflozin) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/type-2-diabetes-mellitus.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Type 2 Diabetes Mellitus FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/type-2-diabetes-mellitus

```bibtex
@misc{secapidev_indications_type_2_diabetes_mellitus_20261116,
  title        = {Type 2 Diabetes Mellitus FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/type-2-diabetes-mellitus}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_type_2_diabetes_mellitus_20261116","title":"Type 2 Diabetes Mellitus FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/type-2-diabetes-mellitus","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
